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Background: To evaluate the efficacy of Endo-Bronchial Valves in the management of persistent air-leaks 
(PALs) and the procedural cost.
Methods: It was a retrospective multicenter study including consecutive patients with PALs for alveolar 
pleural fistula (APF) undergoing valve treatment. We assessed the efficacy and the cost of the procedure.
Results: Seventy-four patients with persistent air leaks due to various etiologies were included in the 
analysis. In all cases the air leaks were severe and refractory to standard treatments. Sixty-seven (91%) 
patients underwent valve treatment obtaining a complete resolution of air-leaks in 59 (88%) patients; a 
reduction of air-leaks in 6 (9%); and no benefits in 2 (3%). The comparison of data before and after valve 
treatment showed a significant reduction of air-leak duration (16.2±8.8 versus 5.0±1.7 days; P<0.0001); chest 
tube removal (16.2±8.8 versus 7.3±2.7 days; P<0.0001); and length of hospital stay (LOS) (16.2±8.8 versus 
9.7±2.8 days; P=0.004). Seven patients not undergoing valve treatment underwent pneumo-peritoneum 
with pleurodesis (n=6) or only pleurodesis (n=1). In only 1 (14%) patient, the chest drainage was removed  
23 days later while the remaining 6 (86%) were discharged with a domiciliary chest drainage removed after 
157±41 days. No significant difference was found in health cost before and after endobronchial valve (EBV) 
implant (P=0.3).
Conclusions: Valve treatment for persistent air leaks is an effective procedure. The reduction of 
hospitalization costs related to early resolution of air-leaks could overcome the procedural cost.
Keywords: Zephyr endobronchial valves (Zephyr EBV); persistent air-leak (PAL); bronchoscopy; alveolar-pleural 
fistula
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Introduction
Persistent air-leak (PAL) is a clinical condition that is due 
to an abnormal communication between the pulmonary 
parenchyma and pleural space that persisted for more than 
5 to 7 days, despite constant drainage of thoracic cavity (1). 
PALs present secondary to various etiologies and treatment 
can be a challenge due to the poor healing ability of diseased 
lung. Surgery with direct repair of the alveolar pleural 
fistula (APF) remains the treatment of choice but most 
patients are not surgical candidates due to poor general 
clinical condition. In 2001 an American College of Chest 
Physicians (ACCP) consensus statement did not recommend 
bronchoscopy for the treatment of PAL (1,2). However, in 
the last two decades encouraging results have been reported 
in small case series (3-12) and review articles (13,14) by the 
use of bronchial valves, originally designed for management 
of emphysema. There are currently 2 commercially available 
types of bronchial valves; the Zephyr endobronchial valve 
(EBV) (Zephyr, Pulmonx Corporation-Redwood City, CA, 
USA) and Spiration intra bronchial valves (IBV) (Olympus 
Respiratory America-Redmond, WA, USA). In the United 
States only the IBV has been approved for humanitarian use 
by the Food and Drug Administration (FDA) for treating 
air-leaks while in Europe the EBV has been approved for 
the management of emphysema and air-leaks. The valves 
differ in shape but have a similar mechanism that consists 
in preventing air entry during inspiration while allowing 
expiratory airflow and drainage of secretions. It limits the 
air-leaks and favors the healing of APF. However, the lack 
of a standard protocol, and its high cost, remain the main 
drawbacks to allow it to be widely used in this procedure 
setting.
Thus, the aim of the present study was to evaluate 
in a large series of patients the efficacy of EBV in the 
management of PALs and the cost of the procedure.
Methods
Study design
This was a multicenter, retrospective study that included 6, 
high-volume Italian centers with relevant experience of the 
EBV procedure. Each participating center has treated more 
than 10 patients. The data of all consecutive patients with 
PALs observed from January 2011 to October 2016 were 
retrospectively reviewed. Inclusion criteria were: (I) patients 
with air-leaks due to APF that persisted for more than 
5 days and were refractory to conventional treatments; (II) 
patients unfit or at high risk for surgery; and (III) PALs that 
could not be controlled by a domiciliary pleural drainage 
system. Exclusion criteria were: (I) patients with PALs due 
to broncho-pleural fistula; and (II) patients with incomplete 
medical record and follow-up. Decisions regarding (I) 
the timing of EBVs implant and removal; (II) chest tube 
management; (III) performing additional procedures in 
case of EBV failure; and (IV) discharge planning were 
not standardized but directed by each participant center 
according to personal experience.
The end-points were: (I) to assess the efficacy of EBV 
treatment in air-leaks resolution and on allowing chest 
drainage removal; and (II) to evaluate the cost of the EBV 
procedure.
All patients were treated with Zephyr EBV (Zephyr, 
Pulmonx Corporation-Redwood City, CA, USA). In Europe, 
CE Mark cleared the use of EBVs for the treatment of 
emphysematous patients, and for damaged lung resulting in 
air-leaks (3-14). Thus, no specific approval by Institutional 
Review Board (IRB) was needed. Each patient signed a 
written informed consent for the treatment, and was aware of 
the pros and cons of procedure. The data, collected by each 
participating center, were retrospectively analyzed. The study 
design was approved by the Ethics Committee of University 
of Campania “Luigi Vanvitelli”, coordinating center of the 
study (Ethical approval number: 833.18).
Study population
The following data were reviewed for each patient: 
demographics; co-morbidities; etiology of PAL [post-
operative, primary spontaneous pneumothorax (PSP), 
secondary spontaneous pneumothorax (SSP),  and 
iatrogenic]; number and size of valves placed; time from 
chest tube placement to valve insertion (days); time 
from valve insertion to chest tube removal (days); length 
of hospital stay (LOS) (days) before and after valve 
deployment; additional interventions in case of EBV failure 
to control air-leaks; time of valve removal (days); and 
morbidity, and mortality related to the procedure. Air-leaks 
were assessed daily along the water compartment of the 
drainage system and classified according to the Cerfolio’s 
classification (15) as following: grade 1 (forced expiratory 
only); grade 2 (expiratory only); grade 3 (inspiratory only); 
grade 4 (continuous). Chest-X ray and/or computed 
tomography scan (according to the preference of each 
treating center) were used to follow-up the target lung re-
expansion after valve implant. When the air-leak stopped 
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following EBV placement, the chest tube was clamped 
for 12–24 hours and then removed, as indicated. Patients 
with PALs also after EBV treatment underwent additional 
treatments that were left to the treating physician. All 
patients were followed-up at 3–6 months for optional valve 
removal.
Procedure of valve implant
The type of anesthesia used during the procedure varied 
across the centers, depending on patient condition, 
and physician preference. Generally, the procedure was 
performed with IV sedation, spontaneous breathing, and 
flexible bronchoscopy. Alternatively, general anesthesia 
with either a laryngeal mask or endotracheal tube to 
provide positive airway pressure was used. To identify 
the source of air-leaks, a Fogarty Catheter was inserted 
into the lobar bronchus suspected of supplying the air-
leak. The catheter balloon was inflated, and the air leak 
rate was assessed through the chest tube 5 minutes later. 
If the air leak reduced, the procedure was repeated in each 
individual segment to identify the exact source of air-leak. If 
more than one segment was identified with an air-leak, the 
primary segment that supplied it was treated first; and if the 
air leak resolved, the remaining segments were not treated. 
Patients with PALs after balloon-occlusion technique were 
excluded from EBV treatment. Two different sizes of valves 
were used: EBV 4.0 and EBV 5.5 for bronchial lumens with 
diameters of 4.0–7.0 mm, and of 5.5–8.5 mm, respectively. 
After measuring the size of the target bronchus, the valve 
was delivered with the Zephyr Delivery Catheter while 
a continuous visual evaluation of the air-leak chamber 
assessed leak reduction.
Cost analysis
The mean cost per patient was calculated based on daily 
hospital cost (€650,00), pharmacy charges (€700 per day 
and €1,700 per day in presence of complications such as 
pneumonia); the valves cost (€3.500 for the smaller EBV 
4.0 valve and €5.500 for the larger EBV 5.5 valve); the cost 
of the valve delivery catheter (€40,000); cost of Fogarty 
Catheter (€1,500); and the cost of operating room and its 
staff (€2,000 per minute).
Statistical analysis
We used the Kolmogorov-Smirnov test and graphic 
histograms to check the normality/skewness of continuous 
variables, and appropriate statistical tests have been chosen 
accordingly. Data were summarized as mean and standard 
deviation (SD) for continuous variables or absolute number 
and percentage for categorical variables. Fisher’s exact test 
and Student t-test was used to compare categorical variables 
and continuous variables, respectively. Multiple comparison 
was made using ANOVA test. A P value <0.05 was 
considered significant. MedCalc statistical software (Version 
12.3, Broekstraat 52; 9030 Mariakerke; Belgium) was used 
for the analysis.
Results
Seventy-seven patients unfit or at increased risk for surgery 
presented PALs during the study period. Of these, three 
patients were excluded from the analysis since the PALs 
were due to a broncho-pleural fistula (n=2), and incomplete 
follow-up (n=1). Thus, 74 patients were included in the 
study (Figure 1). Of these, 67 (91%) patients underwent 
EBV treatment while 7 (9%) patients did not receive valve 
implant since the source of air leaks was not identified 
by balloon occlusion technique. Characteristics of the 
study population are summarized in Table 1. The mean 
age was 64±17 years. The etiology of air-leaks was post-
operative (n=42), SSP (n=24); PSP (n=2); and iatrogenic 
pneumothorax (n=6). Iatrogenic pneumothorax occurred 
in 5 patients after a CT-guided fine-needle aspiration 
Figure 1 Flow chart of the study.
PALs with chest drainage 
(n=77)
Bronchoscopic evaluation 
with balloon occlusion 
(n=74)
Excluded (n=3)
• Bronco-pleural fistula (n=2)
• Incomplete Follow-up (n=1)
Valve placement
(n=67)
No valve placement 
(n=7)
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biopsy to diagnose a lung lesion, and after malposition of 
a nasogastric tube in one patient. All cases of spontaneous 
pneumothorax and post-operative PAL were in the settings 
of compromised lung function and/or poor clinical 
condition that contraindicated the surgical treatment or 
limited its probability of success.
Air leaks characteristics and treatment
Patients undergoing EBV treatment (n=67)
The data are summarized in Table 2. All but two patients 
presented severe air leaks (grade 4). Before valve insertion, 
no reduction of air leaks were observed in all cases, despite 
the use of suction and additional treatments such as 
autologous blood patch pleurodesis (n=8); talc pleurodesis 
(n=11); and pneumoperitoneum (n=6). The mean time from 
chest tube placement to EBV implant was 16.2±8.8 days. 
Nineteen patients had air-leaks for ≥1 week while 48 
patients had air-leaks for ≥2 weeks. Patients with air-
leaks due to iatrogenic pneumothorax were treated earlier 
compared to other subgroups (P=0.0067); 1.2±0.4 valves 
were implanted per patient and most of the procedures 
(92%) were performed with spontaneous breathing and 
moderate sedation. There were no complications or deaths 
during the procedures.
Patients not undergoing EBV treatment (n=7)
All patients presented severe air leaks (grade 4). Six/7 
(86%) patients presented post-operative PALs after 
decortication (n=5) and after lobectomy (n=1), and 1/7 
patient (14%) presented SPP PALs due to emphysematous 
bulla. In addition to chest drainage suction, 6 patients 
(86%) underwent pneumo-peritoneum with blood 
patch pleurodesis (n=3) or talc pleurodesis (n=3), while 1 
patient (14%) received only talc pleurodesis without 
pneumoperitoneum.
Clinical outcomes
Patients undergoing EBV treatment (n=67)
The data are summarized in Table 3. In 59 (88%) patients a 
complete resolution of air-leaks was obtained 2.9±1.4 days 
from valve implant. Six (9%) patients presented a reduction 
of air-leaks (from grade 4 to grade 2) that resolved 
following application of pneumoperitoneum (n=4) or blood 
patch (n=2) 14.6±1.8 days later. Two (3%) patients had 
no reduction of air-leaks, and underwent surgery (n=1) 
or additional valve placement with blood patch (n=1). 
The reduction in air leak allowed these two patients to 
be discharged with a domiciliary chest drainage that was 
removed 70 and 180 days later. The comparison of data 
before and after EBV implant showed significant reduction 
in air leak duration (16.2±8.8 versus 5.0±1.7 days; P<0.0001); 
in chest tube removal (16.2±8.8 versus 7.3±2.7 days; 
Table 1 Characteristics of study population
Variables Values
Patients 74
Male/female 53/21
Age (years) 64±17
Co-morbidity 120*
COPD 59 (49%)
Cancer 36 (30%)
Infectious 11 (9%)
Cardiovascular 7 (6%)
Diabetes 5 (4%)
Systemic rheumatic disease 2 (2%)
Charlson comorbidity index score 4.7±1.6
Asa physical status 2.6±0.7
Causes of air-leaks
Post-operative 42 (57%)
Lobectomy 7 (17%)
Wedge resection 8 (19%)
Sleeve lobectomy 1 (2%)
Decortication 13 (31%)
Bullectomy 13 (31%)
Secondary spontaneous pneumothorax 24 (32%)
Emphysematous bulla 22 (92%)
Cavitary infection process 2 (8%)
Primary spontaneous pneumothorax 2 (3%)
Latrogenic 6 (8%)
After FNAB 5 (83%)
Malposition of nasogastric feeding tube 1 (17%)
*, the sum of the comorbidities is more than 67 since a patient 
could have more than one co-morbidity. COPD, chronic 
obstructive pulmonary disease; ASA, American Society of 
Anaesthesiologist; FNAB, fine-needle aspiration biopsy. 
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P<0.0001); and in LOS (16.2±8.8 versus 9.7±2.8 days; 
P=0.004).
Patients not undergoing EBV treatment (n=7)
Three of seven (43%) patients achieved a mild reduction 
of air-leaks (from grade 4 to grade 3). In only one (14%) 
patient, the chest drainage was removed 23 days later. 
The remaining 6 (86%) patients were discharged with a 
domiciliary chest drainage (mean LOS 47±13 days).
Follow-up
Patients undergoing EBV treatment (n=67)
The mean follow-up time was 37.7±4.1 months. No 
atelectasis of the affected lobe was observed. Only one 
patient presented with hemoptysis that resolved with valve 
removal. The valves were removed in 55/67 (82%) patients 
after a mean time of 134±83 days from the implant using 
flexible bronchoscopy under deep sedation (n=46) or general 
anesthesia (n=9). In all cases, the valves were removed 
during a single session. All the valves were intact at the time 
of removal without any damage, distortion, or missing part. 
No complications or recurrence of air-leaks were observed 
after valve removal. The remaining 12 patients refused to 
have the valves removed. The permanence of valves did not 
cause any complication.
Patients not undergoing EBV treatment (n=7)
In 4 of 6 (67%) patients, the chest drainage was removed 
after a mean of 157±41 days, while the other 2 (33%) 
patients presented an empyema that required thoracoscopic 
decortication.
Table 2 Characteristics of air-leaks in patients undergoing endobronchial valve placement
Variable All Post-surgery
Primary spontaneous 
pneumothorax
Secondary spontaneous 
pneumothorax
Iatrogenic P value
Number 67 36 2 23 6
Chest drainage duration 
before EBV implant 
(days)
16.2±8.8 17±8.4 12.5±3.5 16.1±7.1 8.6±2.3 0.0067
Cerfolio’s scale
Grade 4 65 35 2 22 6 0.94
Grade 3 2 1 0 1 0 – 
Valves per patient 1.2±0.4 1.2±0.6 1.0±0.2 1.3±0.5 1.1±0.3 0.087
Operative time (min) 21±2.9 21±2.4 20±0.3 21±3.9 22±3.8 0.68
Valves placement
RUL 23 (4.5%) 12 (52%) 1 (4%) 9 (39%) 1 (4%) 0.55
RML 3 (8.9%) 1 (33%) 1 (33%) – 1 (33%) 0.004
RLL 6 (9%) 3 (50%) – 3 (50%) – 0.22
LUL 13 (19%) 7 (54%) – 5 (38%) 1 (8%) 0.89
Culmen 4 (6%) 2 (50%) – 1 (25%) 1 (25%) 0.68
Lingula 11 (16%) 6 (55%) – 4 (36%) 1 (9%) 0.93
LLL 6 (9%) 5 (83%) – – 1 (17%) 0.23
RUL + RML 1 (1%) – – 1 (100%) – 0.26
Procedure
Sedation 62 (93%) 32 (52%) 2 (3%) 22 (35%) 6 (10%) 0.64
General anesthesia 5 (7%) 4 (80%) – 1 (20%) – 0.64
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, lower left lobe; RUL + RML, right upper 
lobe and right middle lobe (n=1).
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Cost analysis
The results are summarized in Table 4. The comparison of the 
cost before and after EBV implant showed a significant reduction 
of cost of hospital stay (€10.283±5.104 versus €6.761±1.823; 
P=0.035); and the pharmacy costs (€126±8.9 versus 
€81.3±19.6; P=0.017) after valve treatment. No significant 
difference was found for the entire cost of hospitalization 
before (daily hospital + pharmacy charges) versus after 
EBV implant (daily hospital + pharmacy charges + valves + 
implant catheter + balloon catheter + operative room) with 
total costs of €10.411±5.159 versus €12.132±1.857; P=0.374.
Discussion
The management of PAL is still  a challenge. The 
encouraging results obtained with the use EBV for 
management of PAL are based on few sample reports, 
summarized in Table 5, but none of these reports evaluated 
the cost-effectiveness of this treatment that remains a 
crucial issue considering the valve costs. Due to the low 
incidence of PALs, in order to collect a large number of 
cases, we planned a multicenter study including all high 
volume Italian Centers. Consistent with previous protocols 
(3-11), EBVs were deployed after identification of the air-
Table 3 Outcomes after endobronchial valves treatment
Variable All
Post-
operative
Primary spontaneous 
pneumothorax
Secondary spontaneous 
pneumothorax
Iatrogenic P Value
Number 67 36 2 23 6
Resolution of air-leaks
Complete 59 (88%) 33 (56%) 2 (3%) 18 (31%) 6 (10%) 0.30
Moderate 6 (9%) 2 (33%) – 4 (67%) – 0.34
Persistence 2 (3%) 1 (50%) – 1 (50%) – 0.94
Additional treatments after valve 
implant
8 (12%)
Additional valve + blood-patch 1 (12.5%) – – 1 (100%) – 0.58
Blood patch 2 (25%) 1 (50%) – 1 (50%) – 0.94
Pneumoperitoneum 4 (50%) 1 (25%) – 3 (75%) – 0.36
Surgery 1 (12.5%) 1 (100%) – – – 0.83
Time from valve placement to 
chest drainage removal (days)
7.3±2.7 7.9±1.8 3.5±0.7 7.1±1.1 4.1±0.4 0.16
Time from valve placement to 
discharge (days)
9.7±2.8 9.9±2.3 4.5±0.7 8.4±2.1 5.5±1.3 0.17
Table 4 Analysis of the cost (Euros)
Variables Before valve implant After valve implant P value
Daily hospital stay 10.283±5.104 6.761±1.823 0.035
Pharmacy 126±8.9 81.3±19.6 0.017
EBV valves – 4.477±544
EBV catheter for implant – 441±123
Catheter for occlusion – 15
Operative room charges – 354±121
Total health care 10.411±5.159 12.132±1.857 0.374
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leaks source using the “balloon occlusion” method. We 
occluded only segmental bronchi supplying the source 
of air-leak, and avoided performing a complete lobar 
exclusion in patients undergoing previous lobectomy to 
preserve ventilation in limited residual areas of the lung. 
This strategy reduced the number of valves used compared 
to other studies (3,5-11). Seven patients with unsuccessful 
bronchoscopic identification of air leak source were 
excluded from EBV treatment. Five of these underwent 
pleural decortication that theoretically affected bronchial 
segments of different lobes making it difficult to identify the 
source of the air leak.
The valves were deployed after a median time of 19 days 
from drain insertion, as in other reports (3-11). However, 
19/67 (28%) patients were treated with less than 2 weeks. 
Five patients presented iatrogenic air-leaks related to a 
trans-cutaneous needle biopsy for diagnosing advanced 
lung cancer. Thus, a fast resolution of PALs was required 
to prevent any delay in chemotherapy. Two patients with 
PSP underwent previous operations, and re-interventions 
for treating the recurrence were considered high-risk 
procedures. Twelve patients with SSP had a rupture of 
emphysematous bulla, and they were considered unfit 
for surgery due to severe comorbidities. In all cases, 
the air-leaks were severe (grade 4) and refractory to 
suction drainage, and to additional treatments such as 
autologous blood patch pleurodesis; talc pleurodesis; and 
pneumoperitoneum. Since there is a very low possibility 
of spontaneous resolution therefore supporting early EBV 
treatment is considered as the only strategy to resolve or 
reduce the amount of air leak. After EBV insertion, we 
observed a complete resolution of air-leaks in 59/67 (88%) 
patients. Of these, 40/59 (68%) patients had complete 
resolution within 24 hours after valve placement, and 
19/59 (32%) patients within 7 days without any significant 
difference related to the etiology of air leaks, in line with 
previous studies (3,4,6-11). In 6/67 (9%) patients, EBV 
implant led to a significant reduction in the amount of air 
leak, and adjuvant treatments such as pneumo-peritoneum 
and autologous blood patch facilitated complete resolution.
In 2/67 (3%) patients, EBV treatment failed to resolve 
the air leaks. The presence of collateral ventilation and 
the failure to occlude the target air-way could have been 
the main reason for persistence of air-leaks also after valve 
implant. The significant reduction of the time of chest 
tube removal, and of LOS confirmed the effect of the 
procedure for air leaks control. Our data are consistent with 
prior reports (3,6-9) where the median time from valve 
placement to chest tube removal ranged from 8 to 16 days. 
Only Dooms et al. (5) reported a quicker removal of chest 
tube than the present report. We used a traditional chest 
drainage system with a subjective quantification of air-
leaks, while Dooms et al. (5) used a digital thoracic drainage 
system, with an objective and continuous monitoring 
of the air leak. Furthermore, Dooms et al. (5) restricted 
the indication of valve treatment to patients with “more 
localized” air-leaks since they included only PALs due to 
anatomical lung resection but excluded those caused by PSP, 
SPS or decortication, as in the present study. Thus, these 
differences could explain the different results compared to 
our study.
Consistent with other published series (3-11), the valves 
were removed in 65% of cases and left in place in the 
remaining 35% of patients without any problem. The safety 
of this strategy is supported by other studies, in which valves 
were placed permanently for emphysema or for prolonged 
periods for other medical conditions (13-17).
The cost of EBVs remains the main limitation for their 
large use (18-20). Due to the lack of a control group, to 
evaluate the valve cost we adopted a simple mathematical 
model considering several variables as the daily hospital 
cost before and after valve implant, and the cost of the valve 
procedure. We found that the total cost related to valve 
management was not significantly different than the health 
cost before valve implant. However, if we considered only 
the daily hospital stay cost, a significant reduction after 
valve implant was observed. Since PAL adds significantly 
to health care costs due to the prolonged LOS, in theory 
the reduction of LOS obtained with early EBV treatment 
likely demonstrates the cost effectiveness of this approach. 
Varela et al. (21) calculated that the total prolonged stay 
for patients with PAL after lobectomy (n=23) compared to 
control group (n=215) was 62 days; with an estimated total 
expense resulting from PAL of €39,437.39 (€38,724.96 
hospital stay and €712.43 pharmacy charges). To reduce 
the cost of hospitalization of PALs, a possible strategy is to 
discharge home patients with domiciliary chest drainage 
as supported by Cerfolio et al. (22). It was adopted in 6 of 
our patients who did not undergo EBV treatment, but this 
strategy was not free of expenses; the costs were shifted 
to primary or ambulatory care service as some of these 
patients lived in rural areas away from hospital. In addition, 
2 patients developed pleural empyema that required 
thoracoscopic decortication. PALs patients are prone to 
developing major postoperative morbidity (18,19,21,22). 
In the Varela’s series (21), three out of 23 PAL patients 
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discharged home with domiciliary chest drainage were 
readmitted due to pneumothorax, and or infection that 
could have been related to PAL.
Study limitations
Several limitations of our study did not allow us to draw 
definitive conclusions on the real efficacy of EBV for 
the treatment of PAL. (I) Due to the retrospective and 
multicenter nature of the study, the decision algorithm 
for placing EBV, the experience in valve placement, and 
the decision for planning additional interventions were 
different between the participating centers, and all these 
variables could have affected the final results. (II) Due to the 
lack of standardization in suction level and the subjective 
assessment of air leaks, the timing of chest-tube removal 
was established by the treating physicians rather than being 
guided by predefined criteria. In theory, some patients could 
have unnecessarily had the chest tube in place for more days 
resulting in an underestimation of the clinical benefits of 
valve implantation.
Conclusions
The use of EBV is a promising strategy for treatment 
of PAL. The reduction of LOS obtained with the early 
resolution of air-leaks could justify the costs of the 
procedure. For the success of the treatment, the exact 
identification of the source of the air leaks is mandatory to 
identify the patients who will benefit from this treatment, 
and to reduce the amount of lung parenchyma to 
(temporally) exclude, and the number of valves to implant. 
A prospective trial comparing valve placement versus 
standard of care is currently registered, and recruiting 
patients. The data from this and future prospective studies 
will help to define the real efficacy of this treatment.
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